{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:07:33Z","timestamp":1791310053993,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001901","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:00:00Z","timestamp":1347408000000}}],"reference-count":59,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001901.pub2","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T18:01:40Z","timestamp":1346781700000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review"],"prefix":"10.1002","author":[{"given":"Gashirai K","family":"Mbizvo","sequence":"first","affiliation":[{"name":"University of Liverpool; Institute for Ageing and Chronic Disease; Clinical Sciences Building for Research and Education Lower Lane Liverpool Merseyside UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Dixon","sequence":"additional","affiliation":[{"name":"University of Liverpool; Molecular and Clinical Pharmacology; Clinical Sciences Building for Research and Education Lower Lane Liverpool Merseyside UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L","family":"Hutton","sequence":"additional","affiliation":[{"name":"University of Warwick; Department of Statistics; Coventry UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD001901.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000 mg\/d in patients with refractory seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0002|cit2","unstructured":"UCB Evaluation of the efficacy and tolerability of UCB L059 (1500 mg b.i.d., 500 mg tablets) monotherapy in epileptic patients with complex partial onset seizures, having experienced improved seizure control under add-on treatment: a 60-week (maximum), double-blind, multicenter, responder-selected trial (phase III study, placebo comparator) UCB S.A. Pharma Sector"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0004|cit4","unstructured":"UCB A 24-week multicentered, double-blind, parallel group, add-on study to compare the efficacy and the tolerability of 2 oral daily doses of UCB L059 (2000 mg and 4000 mg tablets) with placebo in patients with refractory epilepsy, followed by a 24-week open-label active treatment UCB S.A. Pharma Sector"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001901.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1528-1157.2000.tb00255.x","article-title":"Effect of levetiracetam on epilepsy-related quality of life: N132 study group","volume":"41","author":"Cramer","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0007|cit7","unstructured":"UCB Evaluation of the efficacy and tolerability of UCB L059 (500 and 1500 mg bid, tablets) add-on treatment in epileptic patients with partial onset seizures: a 38-week, double-blind, placebo-controlled, parallel-group multicenter trial UCB S.A. Pharma Sector"},{"issue":"11","key":"10.1002\/14651858.CD001901.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD001901.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1528-1167.2009.02197.x","article-title":"Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial","volume":"50","author":"Levisohn","year":"2009","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.yebeh.2010.04.017","article-title":"Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial","volume":"18","author":"Loge","year":"2010","journal-title":"Epilepsy & Behavior"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1528-1167.2008.01817.x","article-title":"Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial","volume":"50","author":"Peltola","year":"2009","journal-title":"Epilepsia"},{"issue":"9","key":"10.1002\/14651858.CD001901.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0013|cit13","unstructured":"UCB Evaluation of the efficacy and tolerability of UCB L059 (500 and 1000 mg b.i.d., tablets) add-on treatment in refractory epileptic patients with partial onset seizures: a 32-week double-blind placebo-controlled crossover multicenter trial UCB S.A. Pharma Sector"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2006.00372.x","article-title":"Efficacy and safety of levetiracetam (up to 2000 mg\/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study","volume":"47","author":"Tsai","year":"2006","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1528-1167.2008.01729.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures","volume":"50","author":"Wu","year":"2009","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000197109","article-title":"Efficacy and safety of levetiracetam (3,000 mg\/day) as an adjunctive therapy in Chinese patients with refractory partial seizures","volume":"61","author":"Xiao","year":"2009","journal-title":"European Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.yebeh.2007.10.003","article-title":"Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures","volume":"12","author":"Zhou","year":"2008","journal-title":"Epilepsy & Behavior"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00323-0","article-title":"Dose-response effect of levetiracetam 1000 and 2000mg\/day in partial epilepsy","volume":"48","author":"Boon","year":"2002","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0019|cit19","unstructured":"UCB A double-blind, randomized, placebo-controlled 5 parallel groups, confirmatory trial on the efficacy and safety of Levetiracetam used as add-on therapy at doses of 0.5 to 3g\/day in patients from 16 to 65 years with epilepsy with partial onset seizures under treatment with 1 to 3 anti-epileptic drug(s) UCB Japan Co., Ltd. (RRCE07D0208)"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3805\/jjes.28.3","article-title":"[Multicenter, double-blind, randomized, placebo-controlled study of levetiracetam as add-on therapy in Japanese patients with uncontrolled partial seizures]","volume":"28","author":"Yagi","year":"2010","journal-title":"Journal of the Japan Epilepsy Society."},{"issue":"2","key":"10.1002\/14651858.CD001901.pub2-BIB0021|cit21","first-page":"173","article-title":"Study on the therapeutic effect of levetiracetam as an additive therapy for refractory partial epilepsy and the relativity between levetiracetam and multidrug resistance gene: a randomised double-blind placebo-controlled trial","volume":"9","author":"Zheng","year":"2009","journal-title":"Chinese Journal of Contemporary Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0022|cit22","first-page":"299","article-title":"Behavioral changes associated with levetiracetam use in patients with epilepsy","volume":"42(Suppl 7)","author":"Asconap\u00e9","year":"2001","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia\u00a0"},{"issue":"6","key":"10.1002\/14651858.CD001901.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Brodie MJ Antiepileptic drug therapy the story so far Seizure 2010 650 5","DOI":"10.1016\/j.seizure.2010.10.027"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Burneo JG Tellez-Zenteno J Wiebe S Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence Epilepsy Research 2005 63 74","DOI":"10.1016\/j.eplepsyres.2005.07.002"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub2-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001901","article-title":"Levetiracetam add-on for drug-resistant localization related (partial) epilepsy","author":"Chaisewikul","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD001901.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1528-1157.1998.tb01295.x","article-title":"Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards","volume":"39","author":"Cochrane","year":"1998","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/ern.10.3","article-title":"Levetiracetam: a comprehensive review","volume":"10","author":"Crepeau","year":"2010","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Forsgren L Beghi E Oun A Sillanpaa M The epidemiology of epilepsy in Europe - a systematic review European Journal of Neurology 2005 245 53","DOI":"10.1111\/j.1468-1331.2004.00992.x"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"French JA Kanner AM Bautista J Abou-Khalil B Browne T Harden CL Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology 2004 1252 60","DOI":"10.1212\/01.WNL.0000123693.82339.FC"},{"issue":"6","key":"10.1002\/14651858.CD001901.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1535-7511.2006.00137.x","article-title":"Refractory epilepsy: one size does not fit all","volume":"6","author":"French","year":"2006","journal-title":"Epilepsy Currents\u00a0\/ American Epilepsy Society"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"469-78","DOI":"10.1111\/j.1528-1167.2006.00454.x","article-title":"Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus","volume":"47","author":"Gibbs","year":"2006","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Gillard M Chatelain P Fuks B Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein European Journal of Pharmacology 2006 102 8","DOI":"10.1016\/j.ejphar.2006.02.022"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2009.10.007","article-title":"Placebo responses in randomized trials of antiepileptic drugs","volume":"17","author":"Guekht","year":"2010","journal-title":"Epilepsy & Behavior"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0037|cit37","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005] The Cochrane Collaboration"},{"issue":"10","key":"10.1002\/14651858.CD001901.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.seizure.2011.07.007","article-title":"The impact of epilepsy on children and adult patients' lives: development of a conceptual model from qualitative literature","volume":"20","author":"Kerr","year":"2011","journal-title":"Seizure"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/CPJ.0b013e31823d07d1","article-title":"Treating patients with medically resistant epilepsy","volume":"1","author":"Krauss","year":"2011\u00a0","journal-title":"Neurology Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD001901.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0041|cit41","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Lukyanetz EA Shkryl VM Kostyuk PG Selective blockade of N-type calcium channels by levetiracetam Epilepsia 2002 9 18","DOI":"10.1046\/j.1528-1157.2002.24501.x"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Lynch BA Lambeng N Nocka K Kensel-Hammes P Bajjalieh SM Matagne A The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proceedings of the National Academy of Sciences of the United States of America 2004 9861 6","DOI":"10.1073\/pnas.0308208101"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Mac TL Tran DS Quet F Odermatt P Preux PM Tan CT Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review Lancet Neurology 2007 533 43","DOI":"10.1016\/S1474-4422(07)70127-8"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0045|cit45","unstructured":"Maguire M Marson AG Ramaratnam S Epilepsy (partial) Clinical Evidence (Online) 2011"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0046|cit46","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"McCullagh","year":"1989"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0047|cit47","unstructured":"National Institute for Clinical Excellence NICE Clinical Guideline 137. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care, January 2012 www.guidance.nice.org.uk\/CG137"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Niespodziany I Klitgaard H Margineanu DG Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices Neuroscience Letters 2001 5 8","DOI":"10.1016\/S0304-3940(01)01884-5"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Pellock JM Glauser TA Bebin EM Fountain NB Ritter FJ Coupez RM Pharmacokinetic study of levetiracetam in children Epilepsia 2001 1574 9","DOI":"10.1046\/j.1528-1157.2001.41300.x"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub2-BIB0050|cit50","first-page":"145-146","article-title":"Much ado about something or nothing: behavioral problems with levetiracetam use in epilepsy patients","volume":"4","author":"Penovich","year":"2004","journal-title":"Epilepsy Currents\u00a0\/ American Epilepsy Society"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Preux PM Druet-Cabanac M Epidemiology and aetiology of epilepsy in sub-Saharan Africa Lancet Neurology 2005 21 31","DOI":"10.1016\/S1474-4422(04)00963-9"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1528-1167.2010.02915.x","article-title":"Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis","volume":"52","author":"Rheims","year":"2011","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Rigo JM Hans G Nguyen L Rocher V Belachew S Malgrange B The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents British Journal of Pharmacology 2002 659 72","DOI":"10.1038\/sj.bjp.0704766"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0054|cit54","unstructured":"SANAD-II A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II) www.hta.ac.uk\/2562"},{"issue":"5","key":"10.1002\/14651858.CD001901.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jnnp.61.5.433","article-title":"Epidemiology of the epilepsies","volume":"61","author":"Sander","year":"1996","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD001901.pub2-BIB0056|cit56","unstructured":"Sch\u00fcnemann H Bro\u017cek J Oxman A GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group, 2009 Available from www.cc-ims.net\/gradepro"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001901.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1528-1157.1996.tb06027.x","article-title":"The epidemiology and treatment of chronic and refractory epilepsy","volume":"37","author":"Shorvon","year":"1996","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD001901.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1167.2011.03232.x","article-title":"What is the evidence to use new intravenous AEDs in status epilepticus?","volume":"52","author":"Trinka","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11316250-000000000-00000","article-title":"Levetiracetam in childhood epilepsy","volume":"12","author":"Verrotti","year":"2010","journal-title":"Paediatric Drugs"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001901.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001901.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T18:48:55Z","timestamp":1714330135000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001901.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001901.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717958492.793463893","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717958492.793463028","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,12]]}}}